Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study-Reference-Cited by-同舟云学术

Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study

Published:2024-01-22 Issue:3 Volume:42 Page:371-387
ISSN:0891-8929
Container-title:Clinical Diabetes
language:en
Short-container-title:

Author:

Golembiewski Elizabeth H.¹^ORCID,Garcia Bautista Andrea E.¹,Polley Eric²,Umpierrez Guillermo E.³^ORCID,Galindo Rodolfo J.⁴^ORCID,Brito Juan P.¹⁵,Montori Victor M.¹⁵^ORCID,Gockerman Janet P.⁶,Tesulov Michael⁷,Labatte Bertina⁷,Mickelson Mindy M.⁸,McCoy Rozalina G.⁸⁹^ORCID

Affiliation:

1. 1Knowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN

2. 2Department of Public Health Sciences, University of Chicago, Chicago, IL

3. 3Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA

4. 4Division of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL

5. 5Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, MN

6. 6Patient investigator, Grand Rapids, MI

7. 7Patient investigator, Rochester, MN

8. 8Division of Endocrinology, Diabetes, & Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD

9. 9University of Maryland Institute for Health Computing, Bethesda, MD

Abstract

This mixed-methods study sought to identify pharmacotherapy preferences among 40 noninsulin-treated adults with type 2 diabetes receiving care at two U.S. health care systems. Participants ranked by relative importance various health outcomes and medication attributes and then contextualized their rankings. Most participants ranked blindness (63%), death (60%), heart attack (48%), and heart failure (48%) as the most important health outcomes and glucose-lowering efficacy (68%) as the most important medication attribute, followed by oral administration (45%) and lack of gastrointestinal side effects (38%).

Funder

Patient-Centered Outcomes Research Institute

Publisher

American Diabetes Association

Link

https://diabetesjournals.org/clinical/article-pdf/42/3/371/775202/diaclincd230042.pdf

Reference40 articles.

1. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045;Sun;Diabetes Res Clin Pract,2022

2. 6. Glycemic targets: Standards of Care in Diabetes—2023;ElSayed;Diabetes Care,2023

3. Shared decision making in endocrinology: present and future directions;Rodriguez-Gutierrez;Lancet Diabetes Endocrinol,2016

4. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2023;ElSayed;Diabetes Care,2023

5. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012